Natco Pharma Limited has informed the Exchange regarding a press release dated April 08, 2025, titled "Legal Update regarding RISDIPLAM launch in India.".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has shared a press release dated April 8, 2025, providing a legal update on the launch of RISDIPLAM in India. RISDIPLAM is a well-known drug used to treat Spinal Muscular Atrophy (SMA), originally developed by Roche and marketed globally as Evrysdi. The filing itself only notifies the exchange about the press release, and the detailed legal content (such as court rulings, licensing status, or patent matters) would be found in the press release document. No specific financial numbers, court outcomes, or timeline details are included in this exchange filing.
The outcome of this legal update could influence Natco Pharma's ability to launch a generic or affordable version of Risdiplam in India, which may affect future revenue from this product. Investors should look for the actual press release for specifics on the legal standing, as this filing alone does not indicate whether the development is positive or negative for the company.